PIK3CA and breast carcinoma: Andre F et al. divided 341 patients with advanced breast cancer with PIK3CA mutation into two groups and found that DFS in the alpelisib combined with fulvestrant group was significantly higher than that in the placebo combined with fulvestrant group.